Sorafenib is a multiple-target tyrosine kinase inhibitor (TKI) and can inhibit Raf-1, B-Raf, and kinase activity in the Ras/Raf/MEK/ERK signaling pathways, to further suppress tumor cell proliferation. The gene discussed is MAP2K7; the disease is neoplasm.